LearnGlossaryMarketStocksSuperinvestorsSign in

ERNA

Ernexa Therapeutics Inc.

Healthcare · $1M market cap

Verdict

We can't put a fair value on ERNA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-52.3% a year✗
Sales growth-15.1% a year✗
Free cash flow growth—?
Return on invested capital-41.8%✗

Follow ERNA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: no open-market purchases and 8 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Luther Sanjeev

President and CEO · 2026-08-31

Award

$543K

Ratner Elena

director · 2026-08-31

Award

$27K

Wexler William A.

director · 2026-08-31

Award

$27K

Polinsky David

director · 2026-08-31

Award

$23K

Cicala Peter

director · 2026-08-31

Award

$23K

Show all 8 other filings

Cicala Peter

director · 2026-08-31

Award

$27K

Bristol James Arthur

director · 2026-08-31

Award

$23K

Bristol James Arthur

director · 2026-08-31

Award

$38K

About Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works